Timeline
More in Markets
AstraZeneca licenses lung cancer drug for up to $1.5bn
"AstraZeneca is a leader in treating EGFR-mutated lung cancer, and we are eager to add Zegfrovy to our world-class portfolio", said Dave Fredrickson
Search for companies, sectors, market news and more
Navigate
Browse by Sector
Market reports
Daily reports
Sector reports
Energy & Resources
Financials
Technology
Healthcare
Topics
Top Stocks
Industrials
Consumer
Top Stocks